 |
|
 |
|
|
|
HOME » PRODUCT
DEVELOPMENT: PARTNERS & COLLABORATORS
Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting.
On August 3, 2004 MIGENIX and Cadence Pharmaceuticals, Inc. entered into a Collaboration and License Agreement for the development and commercialization of MX-226 (now called OmigardTM), a compound in Phase III clinical development for the prevention of catheter-related infections. Under the terms of the agreement Cadence has exclusive rights to market and sell MX-226 in North America and Europe. In exchange for these rights, MIGENIX will receive:
In
addition, Cadence will fund the clinical, regulatory, and
commercialization costs related to MX-226 and will assume
responsibility for manufacturing. CUTANEA LIFE SCIENCES, Inc. (Malvern, PA)
A license agreement for the development and commercialization of omiganan for use in dermatological diseases was executed on December 7, 2005 with Cutanea Life Sciences, Inc., (“Cutanea”) a private, dermatological pharmaceutical company based in metropolitan Philadelphia, Pennsylvania. Cutanea is focused on the development and commercialization of novel products to treat diseased and aging skin and is a member of the family of bio/pharmaceutical companies founded in conjunction with Paramount BioSciences, Inc.
Cutanea has initiated a Phase II rosacea clinical trial. The Phase II trial is a randomized, vehicle-controlled, double-blind, multicenter study designed to evaluate the safety and efficacy of CLS001 in up to 240 subjects with papulopustular rosacea. The primary efficacy endpoint is the mean percent reduction in the number of inflammatory lesions. This study is being conducted in the United States, and is expected to be completed by the end of 2007.
Pursuant to the license agreement, MIGENIX can receive up to approximately US$21 million in development and commercialization milestone payments, as well as royalties on net sales. Cutanea received exclusive worldwide rights to develop and market omiganan and its analogues for dermatological indications. Cutanea is responsible for funding all development activities including formulation, clinical, regulatory, and commercialization costs.
The agreement with Wyeth was part of the MitoKor acquisition. Under
the agreement, Wyeth holds an exclusive, worldwide license, as well
as options to obtain a license under certain of MitoKor’s patents to
develop certain estrogens and estrogen-like compounds for the
treatment of human neurodegenerative disease, including Alzheimer's
disease and certain other dementias. Wyeth has funded a Phase III
clinical trial evaluating the use of estrogens to delay the onset
and slow the progression of Alzheimer's disease and certain other
dementias in post-menopausal women. Wyeth paid an up-front license
fee upon execution of the agreement. In addition, the agreement
provides for option exercise fees, preclinical and clinical
milestone payments and royalty and other payments following the
commercial approval of any products developed and launched by Wyeth
under this agreement. Wyeth is obligated to use commercially
reasonable efforts to develop and commercialize one or more products
under this agreement. Wyeth retains the right to terminate this
agreement on a product-by-product basis. Written notice requirements
are either 90 days or 360 days depending on the country and the
status of Wyeth's product marketing efforts. If the agreement is so
terminated by Wyeth, the licensed patent rights revert to us. In December 2003, we completed a license agreement with Spring Bank of Milford, MA, under which Spring Bank acquired exclusive worldwide rights to MX-1313, a dinucleotide under development as a treatment for HBV chronic infections. Under the license agreement, MIGENIX received convertible/redeemable preferred shares in Spring Bank (recorded as a Long Term Investment on the balance sheet at a nominal carrying amount) rights for up to US$3.5 million in milestone payments during development of MX-1313 and royalties upon commercialization. Spring Bank will fund all development and patent costs for MX-1313. Spring Bank has received a US$2.6 million grant from the NIH to advance development of MX-1313.
|
|
 |
|||
